Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004153 (
atherosclerosis
)
77,401
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Very low density lipoprotein receptor
(
VLDLR
) is thought to participate in the pathogenesis of
atherosclerosis
induced by VLDL and beta-VLDL. The present study was undertaken to elucidate the effects of VLDL and beta-VLDL on
VLDLR
expression and its signaling pathway. RAW264.7 cells were incubated with VLDL and beta-VLDL. The expression of
VLDLR
mRNA was detected by RT-PCR. The transcriptional activity of
VLDLR
gene was detected in recombinant plasmid pGL4.2VR-luciferase transfected RAW264.7. Western blot assay was used to detect the changes of phosphorylated ERK1/2 protein. Inhibitors or activators were used to observe the signal pathway involving
VLDLR
expression regulation. The results showed that VLDL and beta-VLDL stimulated ERK1/2 activity in a PKC-dependent manner. VLDL or beta-VLDL-induced
VLDLR
expression on macrophages was extremely abolished by inhibitors ERK1/2 or PKC. Our findings revealed that VLDL or beta-VLDL-induced
VLDLR
expression via PKC/ERK cascades and the effect was linked to the transcriptional activation of
VLDLR
gene promoter.
...
PMID:Up-regulation of VLDL receptor expression and its signaling pathway induced by VLDL and beta-VLDL. 1922 53